News

Filter

Current filters:

Impax LaboratoriesRytary

FDA performs inspection of Impax's Taiwan facility

FDA performs inspection of Impax's Taiwan facility

30-07-2014

The US Food and Drug Administration has performed a general Good Manufacturing Practices (GMP) inspection…

Impax LaboratoriesNeurologicalPharmaceuticalRegulationRytaryUSA

Impax Pharma resubmits NDA for Rytary

Impax Pharma resubmits NDA for Rytary

11-04-2014

Impax Laboratories’ branded products division has resubmitted the New Drug Application for Rytary (carbidopa…

Impax LaboratoriesNeurologicalNorth AmericaPharmaceuticalRegulationRytaryUSA

Patent expiries will push Parkinson’s drug market lower by 2019

17-12-2013

Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s disease (PD)…

GlobalImpax LaboratoriesMarkets & MarketingNeurologicalNewron PharmaPatentsPharmaceuticalpimavanserinRytarysafinamide

Another stumbling block for Impax Pharma's Rytary

22-01-2013

Impax Pharmaceuticals, the branded products division of Impax Laboratories (Nasdaq: IPXL), revealed on…

GlaxoSmithKlineImpax LaboratoriesNeurologicalNorth AmericaPharmaceuticalProductionRegulationRytary

COMPANY SPOTLIGHT

Menarini

Back to top